Skip to main content

Coronavirus: Vaccination

Question for Department of Health and Social Care

UIN 27365, tabled on 5 July 2021

To ask the Secretary of State for Health and Social Care, what (a) advice and (b) support his Department is providing to Novavax covid-19 vaccine trial participants who have been unblinded but do not have access to their antibody test results and are unsure of their level of protection against the covid-19 virus.

Answered on

13 July 2021

Guidance has been provided to support vaccine trial participants who wished to be unblinded at a time when they became eligible for an approved COVID-19 vaccine. This suggests individuals should discuss with the principle investigator at the site in which the participant was recruited who are best placed to advise on the options following unblinding.

In general, participants who only received a placebo would be recommended to receive the deployed COVID-19 vaccine schedule. Those that received a full course of an active vaccine, would be advised that further doses of deployed vaccine were not advisable. Whilst antibody tests were performed in the study, the advice on further vaccination would be based on the record of the participant's previous doses in the trial.